Trilogy International Partners Inc T.TRL.WT.A

Eli Lilly and Axiron end TRT Licensing Agreement

[alwaysmoving]

Here is the link: https://www.thepharmaletter.com/article/lilly-pulls-out-of-licensing-agreement-for-axiron Axiron holds about 14% market share in the US for Testosterone therapy products. Not sure if Axiron will continue to be markreted through Acrux but no doubt their will be a big disturbance here, if 14% market share is up for grabs Natesto could likely hope to gain a good portion of that. Much like was said at the annual meeting 5% market share is equivalent to 100mm in sales, so a nice piece of pie. Also, for those following closely; Aytu has updated their corporate presentation on their website and it includes up to date TRX and NRX values for Natesto prescriptions and it continues to trend higher so great news!